Ravulizumab [Ultomiris]
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Post-marketing information
Patient Alert Card
Patient Medication Guide
Physician Educational Material
Subsidy Information and Financing Scheme
No
Active ingredient: Ravulizumab
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
The Ministry of Health’s Drug Advisory Committee has recommended:
Eculizumab 300 mg concentrate for solution for infusion as monotherapy for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) in adults and children.
Funding status
[R] Eculizumab 300 mg concentrate for solution for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 1 April 2026.
[R] Eculizumab should be used in line with the additional clinical criteria listed in the Annex.
[NR] MAF assistance does not apply to iptacopan or ravulizumab for treating PNH or aHUS.
Post Marketing Information
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch (opens in new tab). The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch (opens in new tab) for the most updated product information. |
Intravenous
* Clinical information is available for this product.